N-ethyl-2-pyrrolidinol | 117449-78-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: N-ethyl-2-pyrrolidinol
• 英文别名: Hydroxyl ethyl pyrrolidine；1-ethylpyrrolidin-2-ol
• CAS: 117449-78-2
• 化学式: C₆H₁₃NO
• 分子量: 115.175
• InChiKey: LFVPWZWOSAFWHK-UHFFFAOYSA-N

物化性质

• 沸点：
  166.0±33.0 °C(Predicted)
• 密度：
  1.007±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-ethyl-2-pyrrolidinol 、 2-氯烟酸 生成 2-(2-Chloroethyl)-4-ethyl-2,3-dihydropyrido[3,2-f][1,4]oxazepin-5(4H)-one hydrochloride
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• [EN] PHENYLAMINOPYRIDINES<br/>[FR] PHENYLAMINOPYRIDINES
  申请人：BASILEA PHARMACEUTICA AG

  公开号：WO2006027348A1

  公开（公告）日：2006-03-16

  The invention relates to novel substituted 3-phenylamino-5-(3-aminophenyl)pyridines and corresponding pyrazines of formula (I), wherein A is CH, C-lower alkyl or N, R1 represents C(=O)R9, S(=O)2R10, P(=O)(OR11)2, optionally substituted phenyl or optionally substituted heteroaryl, and the other substituents have the meaning described in the specification, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of neoplastic diseases and autoimmune diseases, and a method for the treatment of such diseases.

  本发明涉及新型的取代3-苯基氨基-5-(3-氨基苯基)吡啶及其相应的吡嗪，其具有公式(I)，其中A是CH，C-低碳烷基或N，R1代表C(=O)R9，S(=O)2R10，P(=O)(OR11)2，可选地取代的苯基或可选地取代的杂芳基，以及其他取代基的含义如说明书中所述，本发明还涉及它们的制备过程，包含它们的药物组合物，它们的使用，可选地与一个或多个其他药物活性化合物结合用于治疗肿瘤疾病和自身免疫疾病，以及治疗这些疾病的方法。
• [EN] ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ÉTHYLÈNE DIAMINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'HYPOCRÉTINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016100161A1

  公开（公告）日：2016-06-23

  The present invention is directed to ethyldiamne compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及对促进素受体的拮抗剂乙二胺化合物。本发明还涉及所述化合物在潜在的治疗或预防涉及促进素受体的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在的预防或治疗涉及促进素受体的疾病中的用途。
• [EN] TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS<br/>[FR] DÉRIVÉS TRIAZINE POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À DES NEUROTROPHINES
  申请人：ALZECURE PHARMA AB

  公开号：WO2021038241A1

  公开（公告）日：2021-03-04

  There is provided a compound of formula I, (I) wherein R1 and R2 are as defined herein, which compounds are useful in the treatment of diseases characterised by impaired signalling of neurotrophins and/or other trophic factors, such as Alzheimer's disease and the like.

  提供了一个式I的化合物，其中R1和R2如本文所定义，这些化合物在治疗由神经营养因子和/或其他营养因子信号传导受损引起的疾病中很有用，如阿尔茨海默病等。
• Composition for treatment of pathogens that are resistant to tetracyclines
  申请人：Bioversys AG

  公开号：EP2762134A1

  公开（公告）日：2014-08-06

  The invention relates to compounds and pharmaceutical compositions useful in combination with tetracyclines in the treatment of bacterial infections caused by Gram-positive and Gram-negative pathogens, with particular efficacy in tetracycline resistant strains. These compounds specifically bind to TetR and therefore prevent the transcriptional activation of tet resistance genes. The compounds have a potentiating effect on the activity of members of the tetracycline family, in particular of tetracycline, minocycline, doxycycline and tigecycline, in the treatment of tetracycline susceptible, intermediate and tetracycline resistant pathogens.

  该发明涉及与四环素结合在一起用于治疗由革兰氏阳性和革兰氏阴性病原体引起的细菌感染的化合物和药物组合物，对四环素耐药菌株尤为有效。这些化合物特异性地结合到TetR，从而阻止tet耐药基因的转录激活。这些化合物对四环素家族成员的活性具有增强作用，尤其对四环素、米诺环素、多西环素和替加环素在治疗四环素敏感、中间和四环素耐药病原体方面具有增强作用。
• [EN] SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS<br/>[FR] VEMURAFENIB SENSIBLEMENT PUR ET SES SELS
  申请人：SHILPA MEDICARE LTD

  公开号：WO2016083956A1

  公开（公告）日：2016-06-02

  The present Invention relates to a process for the preparation substantially pure propane- 1 -sulfonicacid- 3 -[5 -(4-chiorophenyI)-1 H-pyrrolo [2,3-b]pyridine-3 -carbonyl]-2,4-difluoro-phenyl} -amide or Vemurafenib of Formula (1), The present invention further relates to a process for the preparation substantially pure propane- 1 -sulfonic acid- 3 - [5-(4-chlorophenyi)-1H-pyrrolo [2,3-b]pyridine-3 -carbonyl] -2,4-difluoro-phenyl} -amide trifluoro methane sulfonic acid salt or Vemurafenib triflate of Formula (VII).

  本发明涉及一种制备几乎纯的丙烷-1-磺酸-3-[5-(4-氯苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟苯基}-酰胺或Vemurafenib（式（1））的方法。本发明还涉及一种制备几乎纯的丙烷-1-磺酸-3-[5-(4-氯苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟苯基}-酰胺三氟甲烷磺酸盐或Vemurafenib triflate（式（VII））的方法。